Study reveals impacts of Alzheimer’s disease on the whole body
Peer-Reviewed Publication
Updates every hour. Last Updated: 16-May-2025 13:09 ET (16-May-2025 17:09 GMT/UTC)
While Alzheimer’s disease is mostly considered a disorder of the brain, emerging evidence suggests that the condition also affects other organs of the body. Working with the laboratory fruit fly, researchers at Baylor College of Medicine, the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital (Duncan NRI) and collaborating institutions provide a new understanding of how Alzheimer’s disease affects different tissues across the entire body. The findings, published in Neuron, reveal new insights into brain-body communication in neurodegeneration and pave the way for identifying novel biomarkers and therapeutic targets for Alzheimer’s disease.
A new study reveals that common over-the-counter supplements, popular with male bodybuilders and athletes, may impact their fertility.
Albert Einstein College of Medicine has appointed Britta Will, Ph.D., associate professor of oncology, of medicine and of cell biology, and the Diane and Arthur B. Belfer Scholar in Cancer Research, as the permanent director of the Ruth L. and David S. Gottesman Institute for Stem Cell Research and Regenerative Medicine.
With mitochondrial DNA (mtDNA) base editing tools, this study controlled the nuclear background to investigate the causal effect of mtDNA mutations. Co-existence of wild-type and mutant mtDNA (heteroplasmy) in MT-ND5 was introduced. Enhanced oncogenic potential was confirmed with in vitro and in vivo assays. They reported compromised mitochondrial respiration and increased glycolytic activity, often termed as the Warburg effect following the mutations. By tracking cellular phenotypes during the MT-ND5 heteroplasmy decay, they reasoned that the increased glycolytic activity was to rescue NAD+ depreciation. Increased ROS level, genome instability, altered NAD+ epigenetics are the likely factors drove oncogenesis post MT-ND5 mutations.
Metastatic cancer remains a major cause of death. MT1-MMP is a key enzyme facilitating cancer cells' invasion and spread. Researchers from Yunnan University have made a surprising discovery: the VPS35/Retromer complex regulates MT1-MMP levels through a dual mechanism, both stabilizing the MT1-MMP protein and increasing its transcription via the STAT3 pathway. This leads to increased MT1-MMP levels and accelerates melanoma metastasis. The findings offer a potential new therapeutic target for preventing or treating metastatic cancer.